TWP
CHRS icon

Tyche Wealth Partners’s Coherus Oncology CHRS Stock Holding History

Tyche Wealth Partners’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$282K Sell
201,202
-39,666
-16% -$64.8K 0.04% 273
2026
Q1 		$407K Buy
240,868
+20,000
+9% +$35.5K 0.06% 229
2025
Q4 		$314K Buy
220,868
+25,000
+13% +$36.4K 0.05% 257
2025
Q3 		$321K Sell
195,868
-14,000
-7% -$15.6K 0.06% 223
2025
Q2 		$153K Sell
209,868
-55,898
-21% -$48.3K 0.03% 286
2025
Q1 		$214K Sell
265,766
-1,000
-0.4% -$1.15K 0.05% 263
2024
Q4 		$368K Buy
266,766
+50,864
+24% +$57.1K 0.08% 184
2024
Q3 		$225K Hold
215,902
– – 0.05% 254
2024
Q2 		$374K Hold
215,902
– – 0.09% 161
2024
Q1 		$516K Hold
215,902
– – 0.13% 133
2023
Q4 		$719K Buy
+215,902
New +$578K 0.17% 112

Other funds holding CHRS

TGY2IT
Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $510M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return

Tyche Wealth Partners's CHRS Position: Q2 2026 in Review

Tyche Wealth Partners reduced its Coherus Oncology (CHRS) stake by 16% in Q2 2026, selling an estimated $64.8K and leaving 201,202 shares worth $282K. The position accounts for 0.04% of the portfolio, ranked #273.

Tyche Wealth Partners first reported a position in CHRS in Q4 2023 and has held it in 11 quarters since. The position peaked at $719K in Q4 2023. 147 funds tracked by Wall St. Rank hold CHRS as of Q2 2026.

  • Tyche Wealth Partners held 201,202 shares of Coherus Oncology worth $282K as of Q2 2026.
  • Tyche Wealth Partners sold 39,666 Coherus Oncology shares in Q2 2026, an estimated $64.8K.
  • Coherus Oncology made up 0.04% of Tyche Wealth Partners's portfolio in Q2 2026, its #273 holding.
  • Tyche Wealth Partners first reported a position in Coherus Oncology in Q4 2023 and has held it in 11 quarters since.
  • Tyche Wealth Partners's Coherus Oncology position peaked at $719K in Q4 2023.
  • 147 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2026.

Based on Tyche Wealth Partners's 13F filing for Q2 2026, filed 6 Aug 2026.